Nuvectis Pharma Earns Breakthrough Therapy Status in China for Brain Cancer Treatment NXP200

Nuvectis Pharma Earns Breakthrough Therapy Status in China for Brain Cancer Treatment NXP200 →

Nuvectis Pharma (NASDAQ: NVCT, listed as FNEWS on Investegate) has been awarded Breakthrough Therapy Designation by China's Centre for Drug Evaluation for its oral, brain-penetrant BRAF inhibitor NXP200. This drug targets BRAF V600-mutant,…